^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Gallbladder Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor) +
    lapatinib (EGFR inhibitor, HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    South Asian J Cancer
    Title:

    Genomic Landscape and Targeted Treatment of Gallbladder Cancer: Results of a First Ongoing Prospective Study

    Published date:
    12/14/2020
    Excerpt:
    ...patients of unresectable and/or metastatic GBC of age ≥18 years were enrolled. Four patients with ERBB2 amplification received trastuzumab and/or lapatinib, showed partial response, and maintained response beyond 12 weeks. One patient had mixed response, whereas two patients progressed on trastuzumab and lapatinib.
    DOI:
    10.1055/s-0040-1721180
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    J Int Med Res
    Title:

    Dual-targeting strategy using trastuzumab and lapatinib in a patient with HER2 gene amplification in recurrent metachronous metastatic gallbladder carcinoma

    Published date:
    05/20/2019
    Excerpt:
    ...after dual HER2 targeted therapy with trastuzumab and lapatinib, the follow-up chest and brain MRI revealed that the patient achieved a partial response in brain metastatic tumors (Figure 1c) and lung metastatic tumors...This study demonstrated that HER2 inhibition is a promising therapeutic strategy for GBC with HER2 amplification and, combined with lapatinib...
    DOI:
    10.1177/0300060519847796